EMLA cream is an effective topical anesthetic for bronchoscopy

Benjamin Sohmer MD1, Gregory L Bryson MD FRCP1, Steven Bencze MD FRCP2, Maria Mouroukas Scharf RRCP3

BACKGROUND: EMLA cream (AstraZeneca Inc, Canada) (1:1 eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) has traditionally been used for topical anesthesia of the skin. Recent reports of EMLA’s use for anesthesia of the oral mucosa suggest an application in topical anesthesia for bronchoscopy.

OBJECTIVES: To evaluate the amount of local anesthetic administered during bronchoscopy; to assess the time required to obtain topical anesthesia; to assess the quality of the topical anesthesia as described by bronchoscopists; and to document any complications.

METHODS: Fifty-seven unpremedicated patients had 4 mL of EMLA cream applied to the posterior third of their tongues on arrival in the bronchoscopy suite. Liquid lidocaine was applied through the bronchoscope for laryngeal anesthesia.

RESULTS: The mean time from the application of EMLA cream to insertion of the bronchoscope was 5.10±0.48 min. Fifty-six patients (98.2%) required no supplemental anesthesia. Bronchoscopy conditions were described as ‘excellent’ in 55 cases (96.5%) and ‘good’ in 3 cases (5.3%).

CONCLUSIONS: EMLA is an effective alternative for oropharyngeal topical anesthesia that is well-tolerated by patients.

Key Words: Administration; Anesthesia; Bronchoscopy; EMLA; Lidocaine; Local; Prilocaine; Topical

Clinicians at The Ottawa Hospital (Ottawa, Ontario) have recently adopted EMLA cream for oropharyngeal anesthesia. The purpose of the present study was to evaluate the use of EMLA cream for topical anesthesia of the oropharyngeal mucosa for diagnostic bronchoscopy.

MATERIALS AND METHODS

After The Ottawa Hospital research ethics board approval, the charts of 57 consecutive patients (both inpatients and outpatients) that underwent diagnostic bronchoscopy using EMLA for oropharyngeal topical anesthesia were reviewed retrospectively. All patients arrived in the bronchoscopy suite with intravenous access. No premedication or supplemental intravenous sedation were administered. Oxygen was applied to patients via nasal prongs at 3 L/min. Three-lead electrocardiography and oxygen saturation monitors were applied. EMLA cream (4 mL; 100 mg lidocaine and 100 mg prilocaine) was dispensed into a disposable syringe. Patients were asked to open their mouths with their tongues extended and the cream was applied all at once to the posterior third of the tongue. The cream became less viscous as it mixed with the oropharyngeal mucosa for diagnostic bronchoscopy.

La crème EMLA est une anesthésique topique efficace pour la bronchoscopie

HISTORIQUE : La crème EMLA (AstraZeneca Inc., Canada) (1:1 mélange eutectique de lidocaïne 2,5 % et de prilocaïne 2,5 %) a toujours été utilisée comme anesthésique topique de la peau. Les comptes rendus récents sur l’usage de l’EMLA pour l’anesthésie de la muqueuse orale suggèrent une application pour l’anesthésie topique de la bronchoscopie.

OBJECTIFS : Évaluer la quantité d’anesthésie locale administrée pendant la bronchoscopie, évaluer le temps nécessaire pour obtenir une anesthésie topique, évaluer la qualité de l’anesthésie topique décrite par les bronchoscopistes et documenter les complications.

MÉTHODOLOGIE : Cinquante-sept patients qui n’avaient pas pris de médicaments auparavant se sont fait appliquer 4 mL de crème EMLA sur le tiers postérieur de la langue à leur arrivée au local de bronchoscopie. De la lidocaïne liquide a été appliquée au moyen du bronchoscope pour assurer l’anesthésie du larynx.

RÉSULTATS : Le temps moyen entre l’application de la crème EMLA et l’insertion du bronchoscope était de 5,10±0.48 min. Cinquante-six patients (98,2 %) n’ont pas eu besoin d’anesthésie supplémentaire. Les conditions de bronchoscopie ont été décrites comme « excellentes » dans 55 cas (96,5 %) et de « bonne » dans les deux autres cas (3,5 %).

CONCLUSIONS : La crème EMLA est une solution efficace pour l’anesthésie oropharyngée, et elle est bien tolérée des patients.
saliva. Patients were encouraged to mix and gargle the cream within their oropharynx. Bronchoscopists then gowned, gloved and positioned patients for the procedure. The time from initial EMLA cream application to insertion of bronchoscope was recorded. Patients were asked to expel any remaining oral contents before bronchoscope insertion. For dose calculation purposes, it was assumed that no remaining contents were expelled and the maximal mass of administered drug was recorded. All bronchoscopies were performed orally. On visualization of the larynx, liquid lidocaine was applied through the bronchoscope for laryngeal anesthesia. Adequacy of anesthesia (excellent, fair, good or poor), need for supplemental airway anesthesia, the amount of liquid lidocaine used for laryngeal anesthesia and procedural complications were recorded.

RESULTS

Fifty-seven consecutive patients received topical oral airway anesthesia with EMLA cream. Indications for bronchoscopy were varied and not recorded. Patients ranged in age from 28 to 91 years and their characteristics are described in Table 1. The mass of lidocaine administered at the larynx was 79.65±14.39 mg. Bronchoscopy conditions were described as ‘excellent’ in 55 cases (96.5%) and ‘good’ in the remaining two cases (3.5%). Supplemental oral anesthesia, in the form of four sprays of 2% lidocaine spray, was administered to the oropharynx in one case (1.8%). The remaining 56 cases (98.2%) required no supplementation. The total mass of local anesthetic administered (prilocaine in EMLA, lidocaine in EMLA, laryngeal topical lidocaine and supplemental lidocaine spray) was 280.8±16.8 mg (range 240 mg to 345 mg). The mean time from the application of EMLA cream to insertion of the bronchoscope was 5.10±0.48 min.

DISCUSSION

The scope of EMLA cream’s use is slowly expanding and now includes a recent report (8) of its use for awake fibre optic bronchoscopy. The present study has shown EMLA cream to be an alternative for oropharyngeal topical anesthesia that is effective and well-tolerated by patients, and which decreases the overall mass of local anesthetic required for successful bronchoscopy.

REFERENCES

12. Langmack EL, Martin RJ, Pak J, Kraft M. Serum lidocaine levels did not exceed normal values, which is of concern with prilocaine administration (8).